Cancer Genetics, Inc. Announces Pricing of Public Offering of 1,500,000 Shares of Common Stock
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RUTHERFORD, N.J., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the public offering are expected to be $15,000,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Help employers find you! Check out all the jobs and post your resume.
RUTHERFORD, N.J., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the public offering are expected to be $15,000,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Help employers find you! Check out all the jobs and post your resume.